文献速递痛风与晶体性关节病

痛风患者降尿酸治疗使血尿酸达标与骨折发生风险的关联

Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
PubMed 文献 · Arthritis Rheumatol · 2023-05-25

该研究利用英国初级保健数据库,采用「克隆、删失与加权」方法模拟目标试验,纳入28,554例≥40岁且启动降尿酸治疗的痛风患者。降尿酸至目标水平(<360 μmol/L)组5年髋部骨折风险为0.5%,未达标组为0.8%,风险差-0.3%(95%CI -0.5%, -0.1%),HR 0.66(95%CI 0.46, 0.93)。降尿酸达标与痛风患者骨折发生风险降低相关。

要点

  • 降尿酸治疗使血尿酸达标(<360 μmol/L)组5年髋部骨折风险0.5%,未达标组0.8%。
  • 达标组较未达标组髋部骨折风险差-0.3%(95%CI -0.5%, -0.1%),HR 0.66(95%CI 0.46, 0.93)。
  • 复合骨折、主要骨质疏松性骨折、椎体骨折及非椎体骨折的分析结果与髋部骨折相似。

核心结论

  • 在这项基于人群的研究中,使用降尿酸治疗使血尿酸水平降至指南推荐的目标水平与痛风患者骨折发生风险降低相关。

研究设计与样本

  • 研究采用「克隆、删失与加权」方法模拟目标试验,分析降尿酸治疗使血尿酸达标与骨折风险之间的关联。
  • 数据来源于英国初级保健数据库The Health Improvement Network。
  • 纳入标准为年龄40岁及以上且启动降尿酸治疗的痛风患者,共28,554例。

主要发现

  • 达标组5年髋部骨折风险为0.5%,未达标组为0.8%。
  • 达标组较未达标组髋部骨折风险差为-0.3%(95%CI -0.5%, -0.1%),HR为0.66(95%CI 0.46, 0.93)。
  • 评估复合骨折、主要骨质疏松性骨折、椎体骨折和非椎体骨折时,观察到相似的结果。

关键数值与推荐

  • 血尿酸目标水平为<360 μmoles/liter。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate-lowering therapy (ULT) with the risk of fracture have been inconsistent. We examined whether lowering serum urate (SU) levels with ULT to a target level (i.e., <360 μmoles/liter) reduces the risk of fracture among individuals with gout. METHODS: We emulated analyses of a hypothetical target trial using a "cloning, censoring, and weighting" approach to examine the association between lowering SU with ULT to the target levels and the risk of fracture using data from The Health Improvement Network, a UK primary care database. Individuals with gout who were age 40 years or older and for whom ULT was initiated were included in the study. RESULTS: Among 28,554 people with gout, the 5-year risk of hip fracture was 0.5% for the "achieving the target SU level" arm and 0.8% for the "not achieving the target SU level" arm. The risk difference and hazard ratio for the "achieving the target SU level" arm was -0.3% (95% confidence interval [95% CI] -0.5%, -0.1%) and 0.66 (95% CI 0.46, 0.93), respectively, compared with the "not achieving the target SU level" arm. Similar results were observed when the associations between lowering SU level with ULT to the target levels and the risk of composite fracture, major osteoporotic fracture, vertebral fracture, and nonvertebral fracture were assessed. CONCLUSION: In this population-based study, lowering the SU level with ULT to the guideline-based target level was associated with a lower risk of incident fracture in people with gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wei J, Choi HK, Dalbeth N, et al. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout. Arthritis Rheumatol. 2023. PMID: 36940260. doi:10.1002/art.42504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。